Related by context. All words. (Click for frequent words.) 72 Initiated Phase 69 multicenter phase 69 Randomized Phase 68 GW MILLER 68 Randomized Phase II 67 Randomised 67 ACCLAIM COPD 67 LUX Lung 67 RONG GONG LIN 67 BY DOUGLAS HANKS 67 HCV SPRINT 67 By Linwood Outlaw 66 BY FRANK RADOSEVICH 66 By Denes Husty 66 BY RICH MCCRACKEN 66 BY MARCUS THOMPSON 66 ART THOMPSON 66 Initiate Phase 66 SUPPLEMENTARY DATA SCHEDULE 66 Eldest Inheritance Book 66 Rapeseed Rajasthan #/#.# # 66 denounce Pope Shenouda 66 Multicenter Phase 66 SMITH INTERNATIONAL INC. 65 By Nate Delesline 65 Edwin M. Fayia 65 By JAMES JOYCE 65 Second Pivotal Phase 65 Pivotal Phase II 65 By LEO SHANE 65 BY LAWRENCE LATANE 64 BY GUILLERMO 64 By PAYTON TOWNS 64 BY ADRIAN NEMES 64 Pivotal Phase 64 initiated confirmatory Phase 64 multicentre phase 64 randomized controlled Phase 64 confirmatory Phase 64 By Arek Sarkissian 64 registrational Phase 63 STEALTH C 63 Singer Loudon Wainwright 63 By DENES HUSTY 63 BY ART THOMPSON 63 son Librado Pina 63 multicenter randomized Phase 63 Confirmatory Phase 63 Pooled Analysis 63 Controlled Trial 63 Randomized Double Blind Placebo 63 Randomized Phase III 62 Greek Orthodox Patriarch Theofilos 62 JUDE C. 62 G. Tracy Mehan 62 hGH CTP Phase 62 Intervention Effectiveness 62 Hormone Refractory Prostate Cancer 62 Dose Ranging 62 unresectable stage 62 Raymond A. Partsch 62 I. INTRODUCTION 62 Charles L. Dimmler 62 R. Karman 62 Frank Radosevich 62 RECORD1 62 Lyle Howey 62 G. CHAMBERS WILLIAMS 62 JAMES H. BURNETT 62 GLOBAL MARKET PERSPECTIVE 62 STAR WARS ARCHIVES EPISODES 62 Columbus Dispatch Doral Chenoweth 61 controlled multicenter Phase 61 Trial Evaluating 61 TJ HEALY 61 Randomized Double blind 61 M. HOPPER 61 Blind Placebo Controlled Trial 61 THE GODFATHER PART 61 Multicenter Randomized 61 stage IIIB 61 Roger DuPuis 61 STAFF WRITER @ tidewaternews.com 61 ASSIGNMENT OF ERROR 61 REUTERS Claro Cortes 61 D NON SUPPORT 61 Amos Morale 61 multicenter Phase 61 HCV RESPOND 2 60 Table Tennis Vol 60 Piazza Vittorio Emanuele 60 Commences Phase 60 phase Ib 60 DYNAMICS RESEARCH CORPORATION CONDENSED 60 B. Henneman 60 Oral Fingolimod 60 stage IIIb 60 Interfax Patriarch Alexy 60 J Clin Oncol 60 Gilbert Dewey Gaedcke 60 Initiate Phase III 60 Successfully Completes Phase 60 Double Blind Placebo 60 blinded randomized placebo controlled 60 MACQUARIE DEVELOPMENT CAPITAL 60 IMPACT IMmunotherapy 60 Phase 2b Clinical Trial 60 Reporter Daarel Burnette 60 Danilo V. Adorador 60 By MARCUS THOMPSON 60 CALERIE 60 Timothy W. Scee 60 COPERNICUS 60 Study Evaluating 60 Plus Ribavirin 60 BY FW MANNING 60 ExTRACT TIMI 60 LUCAS L. JOHNSON 60 multicentre randomized 59 Arch Neurol 59 B. Jemmott 59 Meets Primary Endpoint 59 multicenter randomized controlled 59 OrionGadgets HTC Shadow 59 William C. Eacho 59 RE SPEARS 59 His Holiness Pope Shenouda 59 comparing alemtuzumab 59 Placebo Controlled 59 CCX# B 59 BIBW 59 Topline Results 59 Randomized Evaluation 59 initiate multicenter 59 NSABP B 59 initiate multicenter Phase 59 Randomized Clinical Trial 59 EURIDIS 59 Ann Oncol 59 Stent Restenosis 59 OSCAR WELLS GABRIEL 59 Charles Divita 59 C. SINGLETON 59 Lone Star Derby gr. 59 Randomized controlled 59 Aflibercept 59 Suppl. 59 JACK HILL 59 THOMAS H. MAUGH 59 QUASAR validation study 59 ALSYMPCA 59 Paramount Pictures Mission Impossible 59 placebo controlled multicenter 59 Pharmacokinetic Study 59 landmark ATHENA 59 Prospective Randomized Trial 59 E. NEAL 59 Ann Rheum Dis 59 Prognostic Significance 59 Universite Montpellier 59 Refractory Angina 59 RECENT INDUSTRY ACTIVITY 59 Henry Powderly 59 William F. Shughart 59 placebo controlled Phase 59 By GIB SNYDER 59 Dose Escalation 59 RE MODEL 59 John W. Debelius 59 Dinner Theatre Goodfield 59 Randomized Study 59 Ozarelix 58 By WES WOODS 58 KENNETH C. CROWE 58 By EB FURGURSON 58 label multicenter Phase 58 RE LY 58 #,# ton KDX 58 First Patient Enrolled 58 Datuk Mohamed Yusof 58 Randomized Controlled 58 calcium calmodulin dependent 58 Placebo controlled 58 ALLEN POWELL 58 G. ROBINSON 58 Multicenter Randomized Double 58 Catholicos Patriarch Ilia 58 Peginterferon Alfa 2a 58 Clin Oncol 58 Patriarch Alexis 58 Adjuvant Treatment 58 Operation Pangea 58 Iroquois Stakes gr. 58 Nat Genet 58 Myocardial Infarction Study 58 Phase 1b Clinical Trial 58 FASEB J. 58 Prospective Randomized 58 Antigen Specific 58 JAK Inhibitor 58 Antiviral Activity 58 NEVO RES 58 Controlled Study 58 metastatic hormone refractory 58 Defending champion Tommy Armour 58 By ROSCOE BARNES 58 riociguat 58 PIMCO Municipal Income 58 Patients Enrolled 58 STRIDE PD 58 Sorafenib HCC Assessment 58 Includes Corresponding Graph Chart 58 Prostate AdenoCarcinoma Treatment 58 Obes Res 58 CAPITAL ACCOUNT 58 TAXUS IV 58 ADMIRE HF 58 randomized multicentre 58 Multicenter 58 BRIM3 58 AVOREN 58 armodafinil Tablets C 57 Paul Steigleder 57 TMC# C# 57 Antitumor activity 57 Colibri II 57 Martin Kady 57 HYVET 57 dose escalation clinical 57 Sipuleucel T 57 novel VDA molecule 57 Clinical Outcome 57 Advaxis Phase 57 Thromb Haemost 57 randomized multicenter trial 57 J Child Adolesc 57 Placebo Controlled Trial 57 Content Outline 57 evaluating Vectibix 57 Liraglutide Effect 57 Dose Ranging Study 57 fosbretabulin 57 Double Blind Randomized 57 ArchAndroid Suites II 57 treatment naive genotype 57 Cardiac Biomarkers 57 FINANCIAL PROMOTION ORDER 57 BrahMos Block 57 Chief Pablo Labra 57 Intervention Trial 57 Phase III Pivotal 57 Subgroup Analysis 57 Elias Torrez 57 PEG IFN 57 Emperor Manuel Paleologos 57 Commence Phase 57 Multiple Ascending Dose 57 Thomas H. Maugh 57 Nephrol Dial Transplant 57 Completes Patient Enrollment 57 Arch Dermatol 57 Suppl 57 Cancer Res 57 Randomized Placebo controlled 57 Phase Ib II 57 Placebo Controlled Study 57 J Clin 57 John M. Hoober 57 Diabetic Nephropathy 57 Antiviral Therapy 57 phase IIIb 57 unfractionated heparin UFH 57 Relapsing Multiple Sclerosis 57 randomized multicenter 57 Solvency II Basel 57 Carotid Stenting 57 Oral Calcitonin 57 Meta Analysis 57 KEM Album 57 Initiates Phase 57 J. Ihlenfeld 57 multicentre randomized controlled 57 Pivotal Phase III 57 de Madrid UC3M 57 Vasc 57 Perifosine KRX 57 centrist Simeon 56 Randomized Double Blind 56 5alpha reductase 56 Novel Oral 56 dependent kinase inhibitor 56 Phase IIIb 56 multicenter Phase II 56 Pharmacokinetic 56 Safinamide 56 PEGylated interferon beta 1a 56 CORLUX potent GR 56 INTRODUCTION I. 56 Relapsed Multiple Myeloma 56 Chile Atacama Region 56 publisher Orage Quarles 56 Allbanc Split Corp. 56 THE HANGOVER PART 56 SORT OUT 56 Diabet Med 56 Biol Psychiatry 56 J Am Coll 56 Prognostic Factors 56 UPDRS II 56 Aggressive Reduction 56 treatment naïve genotype 56 Preclinical Models 56 genotype 1a 56 complement inhibitor eculizumab 56 MATTEL INC. AND SUBSIDIARIES 56 BOLDER II 56 IV NSCLC 56 Initiates Phase II 56 Metastatic Melanoma 56 R. Staab 56 Fulvestrant 56 Free Full Text 56 Phase 2b Study 56 Joseph A. Fluehr 56 J Am Soc 56 Lung Cancer Trial 56 Clinical Efficacy 56 receptor tyrosine kinase inhibitor 56 #.# AJ Foyt 56 J Clin Endocrinol Metab 56 statue portrays Amenhotep 56 Unfractionated Heparin 56 BRIM2 56 Antitumor Activity 56 Safety Tolerability 56 megahertz Pentium 56 somatostatin analog 56 Metastatic Colorectal Cancer 56 CAMMS# 56 TUI Mein Schiff 56 XIENCE TM 56 III • dhusty@news-press.com 56 Cardiovascular Outcomes 56 Randomized Comparison 56 abstr 56 john @ baltsun.com 56 #:#-# [018] 56 PRE SURGE 56 J Am Acad 56 AZX# Phase 56 Phase 2a Clinical Trial 56 NYHA Class II 56 Vitro Activity 56 EyeGate R 56 NYHA Class 56 recurrent glioblastoma multiforme 56 + Perifosine Evaluation 56 BCom Part 56 ACCEDE 56 FREEDOMS 56 randomized Phase 2b 56 Soft Tissue Sarcoma 56 Solstice Bare 56 Adjuvant Chemotherapy 56 NV Statutory 56 Novel Inhibitor 56 FOCUS ON SELECT PLAYERS 56 MAGE A3 ASCI 56 IIa clinical 56 Antihypertensive 56 BiovaxID Phase 56 Castration Resistant Prostate Cancer 56 Renal Cell Carcinoma 56 Prospective Multicenter 56 Phase IIA 56 II Clinical Trial 56 Nephrol 56 Fixed Dose 56 Mililani Recreation 56 multicenter randomized placebo controlled 56 LUMINATE 56 Relapsing Remitting Multiple Sclerosis 56 Evidence Therapeutic Level 56 #:#-# [019] 56 Edge STudy 56 Intracranial Aneurysms 56 Initiates Phase III 56 metastatic castration resistant 56 By SL FRISBIE 56 Stage IIB 56 REVIVE Diabetes 56 Peginterferon 55 plus prednisone 55 Blind Placebo Controlled 55 Anti Tumor 55 Recombinant Activated Factor 55 Randomized Clinical Trials 55 Syncria R 55 Benign Prostatic Hyperplasia 55 prostate cancer HRPC 55 Pivotal Trial 55 Rong Gong Lin 55 Aurora Kinase 55 aboard L' Acadien 55 Peter J. Prygelski 55 Cardiol 55 Rheumatol 55 ROCKET AF 55 Long Term Efficacy 55 ENDEAVOR IV 55 Bayer HealthCare Onyx Pharmaceuticals 55 Subgroup analysis 55 Phase 2b Trial 55 Diamyd Medical Diamyd 55 EXECUTIVE SUMMARY 55 #:#-# [023] 55 dose escalation Phase 55 Phase III Trial 55 SPEAR Study 55 Combination REOLYSIN R 55 Advanced Renal Cell 55 Novel Therapeutic 55 Coptic Pope Shenouda 55 initiated Phase Ib 55 familial amyloidotic polyneuropathy FAP 55 IMPACT DCM 55 Tyrosine Kinase Inhibitor 55 MKC# MT 55 raucous Quicken Loans 55 Expert Collision Repair 55 BiTE antibody MT# 55 JOHN M. HOOBER 55 Anti Tumor Activity 55 Diagnostic Radiopharmaceuticals 55 Phospholipase 55 Eur Urol 55 Anticancer Drug 55 Metastatic Renal Cell Carcinoma 55 APEX PD 55 TLUS 55 MADIT II 55 APPRAISE 55 LAKE IROQUOIS 55 EVEREST II 55 Left Ventricular Dysfunction 55 Pharmacodynamics 55 Long Lesion 55 Nashua Stakes gr. 55 Senators Manuel Roxas 55 TAXUS ATLAS 55 multicentre randomized double 55 First Patient Dosed 55 phase IIb clinical 55 EOquin TM phase 55 Infarct 55 MANILA Philippines Benigno Aquino 55 prospective randomized placebo 55 paclitaxel poliglumex 55 Sirolimus Eluting Stent 55 Severe Sepsis 55 Non Alcoholic Steatohepatitis 55 evaluating ASA# 55 Hepatocellular Carcinoma 55 PFO migraine 55 Attenuates 55 Neurol 55 Pegylated Liposomal Doxorubicin 55 prospective randomized multicenter 55 Advanced Melanoma 55 Receptor Antagonists 55 CLARITY TIMI 55 Novel Small Molecule 55 Phase IIIb clinical 55 #:#-# [016] 55 multicenter placebo controlled 55 nab paclitaxel 55 Phase III HEAT 55 Burlie L. Sholar 55 Potent Antiviral Activity 55 Clostridium difficile Infection 55 TG MV 55 Treating Chronic 55 Ibritumomab Tiuxetan 55 Antiangiogenic 55 By JENNIFER LEARN 55 ADVANCE ILLUMINATE 55 nonrandomized 55 Gynecol Oncol 55 Pharmacodynamic 55 Clinical Trial Results 55 Arch Intern Med 55 Dose Escalation Study 55 Wilson P. Dizard 55 Gastric Cancer 55 Diabetic Macular Edema 55 Prolongs Survival 55 Metabolic Efficiency 55 Topics Covered I. INTRODUCTION 55 J Pediatr 55 Mycophenolate Mofetil 55 BNS Split Corp. 55 Phase Ib Clinical Trial 55 Relapsed Refractory 55 J Rheumatol 55 fentanyl citrate C 55 Carlos Barbas 55 APF# Phase 55 #:#-# [002] 55 GOUT 54 Prospective Randomized Study 54 Indiana Verdell Jones 54 #a #a [003] 54 C #A Globemaster 54 CLARITY study 54 Boricua Invasion 54 AV CTL Division 54 Eur Respir J 54 Late Breaker 54 #-# Full Text 54 PEGylated Fab fragment 54 Chronic Hepatitis C 54 asymptomatic metastatic 54 relapsing remitting MS RRMS 54 Randomized Controlled Trials 54 documented unresectable 54 Phase Ib IIa 54 Refractory Hodgkin Lymphoma 54 Am J Epidemiol 54 TRANSFORMS 54 Investigational Drug 54 5 fluorouracil leucovorin 54 Prevent Stroke 54 Malignant Melanoma 54 Custirsen 54 RADIANT 54 Zainal Abiden 54 Central Retinal Vein 54 oral transmucosal fentanyl citrate 54 Datuk Mohd Yusof Zainal 54 relapsed MM 54 Teva Provides Update 54 Crit Rev 54 Sustained Efficacy 54 Undersecretary Francisco Baraan 54 stage IIIb IV 54 Phase 1b clinical trials 54 relapsed refractory multiple myeloma 54 Solid Tumors 54 prospective multicentre 54 Clinical Trial Evaluating 54 Risk Stratification 54 keloid scarring 54 Phase IIb Clinical Trial 54 Cloretazine ® 54 MERITS 54 Statistically Significant 54 Chronic Lymphocytic Leukemia 54 prucalopride 54 Sapacitabine 54 evaluating tesamorelin 54 Male Condoms 54 Romidepsin 54 MEND CABG II 54 Immunosuppression 54 Decitabine 54 Cutaneous T 54 Apparel NASDAQ GIII 54 tocilizumab 54 evaluating satraplatin plus 54 J Clin Psychiatry 54 Picoplatin Efficacy After 54 AMVISC ® AMVISC ® 54 EQUATE OB 54 James M. Papada 54 Harold F. Closz 54 KBL Healthcare 54 J Nutr 54 Trabectedin 54 phase IIa 54 Thomas B. McCoun 54 outerwear dresses 54 Raw #/#/# Punjab 54 drug pipeline TAFA# 54 Degarelix 54 Dose Response 54 Orally Active 54 Node Positive 54 Bortezomib 54 Glufosfamide 54 multicenter randomized clinical 54 multicenter Phase III 54 Pediatr 54 3i LON 54 Androxal TM 54 ORAL Solo 54 Multicenter Study 54 Intravenous Equipment 54 Pralatrexate 54 Lupus Nephritis 54 Photo Hayne Palmour 54 Omacetaxine 54 James P. MacElree 54 Randomised Controlled Trial 54 Teesta Low 54 Genes Predict 54 RI Prichard 54 Senator Teofisto Guingona 54 Thomas F. Zenty 54 Ziprasidone 54 agonistic human 54 SPIRIT FIRST 54 Capsulitis 54 annexin 54 Testosterone MDTS ® 54 Ranolazine 54 Cancer Cachexia 54 Systemic Sclerosis 54 Patients Treated With 54 Paco Ignacio Taibo 54 Carotid Revascularization Endarterectomy vs. 54 orally administered inhibitor 54 HBeAg positive chronic hepatitis 54 comparing XIENCE V 54 Randomized 54 Eur J 54 PRTX 54 Ophena TM 54 Kinase Inhibitors 54 multicenter multinational 54 phase IIb 54 Adjuvant Therapy 54 IWLCA Division 54 Collagen Type 54 Localized Prostate Cancer 54 Tipranavir 54 Phase III ADT 54 Insulin Glargine 54 Hematological Cancers 54 Wars Episode 54 ATTRACT 54 oral rivaroxaban 54 Phase III Clinical Trial 54 Testosterone MDTS R 54 virus HCV protease inhibitor 54 Swazi King Mswati 54 Antitumor 54 Stainless Steel Drivers 54 By LUCAS L. 54 :2 54 Treatment Naive HIV 54 Bezielle 54 H. Marburger 53 Percutaneous Coronary Intervention 53 MV Hannibal 53 randomized controlled multicenter 53 under NHDP Phase 53 #:#-# [037] 53 Preclinical Study 53 unresectable Stage III 53 Eur J Cancer 53 Acute Myocardial Infarction 53 CALGB # [002] 53 interferon gamma 1b 53 Neurosurg 53 Poster Discussion 53 Vascular Inflammation 53 Obstet Gynecol 53 Dose Finding 53 R# #mg BID 53 INSPIRE Trial Phase III 53 Aneurysm Repair 53 Efficacy 53 naïve HCV 53 Phase IIb III 53 Luramist TM 53 Dose Limiting Toxicity DLT 53 Albert Gaude 53 XL# SAR# 53 AEG# 53 metastatic GIST 53 biliary tract cancer 53 Withers Stakes gr. 53 Tesamorelin 53 Heterozygous Familial Hypercholesterolemia 53 Prednisone Against Refractory 53 ADVANCE PD 53 BAL# [002] 53 Tanespimycin 53 AVCTL Division 53 Previously Treated 53 Pemetrexed 53 Study Showed 53 Phase III multicenter 53 ACTEMRA TM 53 ZYBRESTAT TM 53 Phase III Pivotal Trial 53 Product Introductions Innovations 53 q#h 53 E. Powderly 53 J Virol 53 Humanized Anti 53 Nat Rev 53 Inflammatory Pain 53 ERRED WHEN IT 53 Amrubicin 53 Edward B. Cloues 53 Acute Heart Failure 53 Fast Skeletal Troponin 53 RIBBON 53 PRoFESS 53 Pivotal Trials 53 Demonstrates Efficacy 53 J Affect Disord 53 Vildagliptin 53 ADAGIO 53 Prognostic Value 53 ARRY # 53 AAG geldanamycin analog 53 Multicenter Trial 53 Maximum Tolerated Dose MTD 53 Cancer Incidence Mortality 53 Intracerebral 53 MEND CABG 53 systemic anaplastic large 53 Non inferiority 53 Tremisis Energy 53 Myelodysplastic Syndrome MDS 53 REALiS SX7 Mark 53 Cell Lymphoma 53 Myeloma Patients 53 Treatment Naive Patients 53 Investigational Agent 53 J Consult Clin 53 NHDP Phase 53 Novel Mechanism 53 Hsp# Inhibitor 53 Randomized Controlled Trial 53 essential blepharospasm 53 multicentric 53 PRECiSE 53 GISSI 53 EXECUTIVE SUMMARY II 53 Demonstrates Sustained 53 Completes Enrollment 53 CHAMPION PCI 53 recurrent malignant glioma 53 Diabetic Foot Ulcer 53 Tiotropium 53 Psychiatry Clin Neurosci 53 Downing Protected VCT 53 PSMA ADC 53 Pharmacokinetic Pharmacodynamic 53 Oncol 53 XpandR 53 Phase 2a Trial 53 Genotype 53 CHMP Opinion 53 Investigational Compound 53 Am J Geriatr 53 Exelixis XL# 53 TLK# 53 RE LY ® 53 Bipolar Depression 53 aminotransferase 53 Polymerase Inhibitor 53 Pharmacokinetic PK 53 Apaziquone 53 Initiates Phase 2b 53 NJSA 2C :2 53 Lesotho King Letsie 53 ENGAGE AF TIMI 53 Hypoactive Sexual Desire Disorder 53 Epratuzumab 53 Motesanib 53 Phase IIB 53 novel tubulin binding 53 Phase IIb Trial 53 PERSEUS 53 Proc Am Soc 53 Empatic ™ 53 Cochrane Database Syst Rev. 53 multicenter randomized 53 humanized interleukin 6 53 Protease Inhibitor 53 Releasing Factor 53 Universidad Carlos 53 IIb 53 Jazzman Chronicles Volumes 53 ISAR REACT 53 Aplidin R 53 NYHA Class III 53 Nat Clin Pract 53 TO AVOID PREGNANCY WHILE 53 Neurosci 53 Sirolimus Eluting 53 Armenian Patriarch Mesrob 53 multicenter prospective 53 assessing T DM1 53 EXPLORE Xa 53 Curr Opin 53 Endocrinol 53 candidate Aquilino Koko 53 All Armenians Garegin 53 REYATAZ r 53 Interferon Alfa 53 Fibrinogen 53 Plus STAARVISC TM 53 subanalysis 53 VICTOR E3 53 Phase Ib clinical 53 Thiazolidinediones 53 Glioblastoma Multiforme 53 evaluating mipomersen 53 Oral Session 53 Crit Care 53 ST Elevation Acute 53 Abstract Number 53 Xeloda ® 53 Kinase Inhibitor 53 Anti CD# Antibody 53 Colorectal Cancer Patients 53 phase IIb III 53 PROTECT AF 53 Systematic Review 53 Resistant Hypertension 53 Left Ventricular 53 pharmacokinetic PK study 53 D. Acklin 53 dasatinib Sprycel ® 53 Demonstrated Significant 53 Therapeutic Efficacy 53 Forodesine 53 Benigno Simeon Noynoy Aquino 53 cancer mCRC 53 metastatic castrate resistant 53 Gastrointestinal Stromal Tumors 53 Sam Fulwood 53 ZYBRESTAT fosbretabulin 53 Sustained virologic response 53 Granted Orphan Drug 53 Dwyer Stakes gr. 53 Prosecution Rests Case 53 HGS ETR2 53 PARGLUVA 53 Enabled POS Terminals 53 Mimetics 52 PREVAIL 52 Temsirolimus 52 intravesical infusion therapy 52 TKB# 52 EGFR HER2 52 Oncolytic Reovirus 52 VI Infrared 52 Bivalirudin 52 Predict Prostate Cancer 52 Col. Lewis Setliff 52 Hypertensive Patients 52 Complicated Skin 52 Nutrition Survey NHANES 52 Heart Failure Patients 52 TONIGHT 'S MUST SEE 52 Tomahawk Strike 52 Advanced Solid Tumors 52 CYP#A# CYP#D# 52 Oral Cavity 52 recombinant PSMA vaccine 52 Ann Intern Med 52 induced macular edema 52 Ramon Ocasio 52 Alvaton Ky. 52 Atypical Hemolytic Uremic Syndrome 52 PEGINTRON TM 52 Advanced Colorectal Cancer 52 double blinded placebo 52 Nilotinib 52 Progenitor Cells 52 Adjunctive Therapy 52 ST Segment Elevation 52 CONQUER OB 52 Myelofibrosis 52 visit http:/www.clinicaltrials.gov/ 52 5 Fluorouracil 52 ELACYT 52 IFN α 52 CATIE AD 52 John M. Solovan 52 vesicular monoamine transporter 52 Restenosis 52 receptor blockers ARBs 52 Linagliptin 52 Chronic Myeloid Leukemia 52 Frank A. Sedita 52 Biol 52 adecatumumab MT# 52 Randomized Trials 52 Cancer Antigen 52 Vertebral Fractures 52 Spectrum Pharmaceuticals Announces 52 tesmilifene 52 oral Janus kinase 52 R roscovitine 52 Angiographic 52 evaluating Actimmune 52 AMVISC R AMVISC R 52 CIMZIA TM certolizumab pegol 52 Stable Angina 52 Phase #b/#a clinical 52 alvespimycin 52 Bevacizumab 52 Xian Lu 52 CYT# potent vascular disrupting 52 ASSERT 52 3rd edn 52 Paclitaxel Carboplatin 52 Bosutinib 52 Myocardial Infarction 52 Versus Placebo 52 MoxDuo R 52 NIH SBIR Phase 52 Ischemic Stroke 52 Prospective Randomized Double 52 Reiki Level 52 Trafigura Ventures 52 I. INTRODUCTION METHODOLOGY 52 Engage Analytics 52 Medidur TM FA 52 Phase Ib 52 John H. Marburger 52 candesartan cilexetil 52 CML CP 52 Renal Function 52 dextromethorphan quinidine 52 phase IIa clinical 52 phase III ACCLAIM 52 lead Aganocide compound 52 Long Term Outcomes 52 Hemodialysis Patients 52 Damien Omen 52 Hematological 52 LymphoStat B belimumab 52 Patency 52 Patients Treated 52 Psychosom Med 52 PRODUCT INNOVATIONS INTRODUCTIONS 52 TEMSO 52 ORMD 52 Enzastaurin 52 Fantasy Stakes gr. 52 multicentre 52 5HT 52 George Brent Mickum 52 Inflammatory Markers 52 ONCONASE R 52 Trandolapril 52 Comet Assay 52 AVN# Phase 52 metastatic HRPC 52 evaluating T DM1 52 Telaprevir VX 52 OR PROPERTY DAMAGE 52 Cardiotoxicity 52 Nephropathy 52 Sustained Virologic Response 52 Henry Zaytoun 52 Lymphocytic 52 Immunomodulatory 52 See id 52 Achieves Primary Endpoint 52 Glatiramer Acetate 52 Acute Ischemic Stroke 52 includes correspondingGraph Chart 52 Crit Care Med 52 disc Tha Carter 52 isavuconazole 52 Genetic Variation 52 Int J Epidemiol 52 DWS RREEF 52 Diabetes mellitus type 52 Orthostatic Hypotension 52 See CLINICAL PHARMACOLOGY 52 Excelsior Venture Partners 52 Jury Deliberations Begin 52 Pivotal Study 52 Dermatol 52 Septic Shock 52 Slow Progression 52 Vicriviroc 52 placebo controlled dose escalation 52 Balloon Angioplasty 52 Councilman Ed Larvadain 52 prosecutor Stuart Dunnings 52 NJSA 2C :5 52 Appears Safe 52 Myocardial Ischemia 52 Brentuximab Vedotin SGN 52 Targeted Therapy 52 J Allergy Clin 52 GSF Development Driller 52 refractory NSCLC